Bromide

Bromide

SCHEMBL3548835

Br.Oc1cc2c(cc1O)C(Cc1ccc(-c3ccc(-c4ccccc4)cc3)cc1)NCC2

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ADRB2 known ✓ P07550 7/20 0.82
ADRB1 known ✓ P08588 2/20 0.67
ADRB3 known ✓ P13945 1/20 0.67
DRD2 P14416 2/20 0.74
DRD4 P21917 2/20 0.74
KDM1A O60341 2/20 0.74
TBXA2R P21731 7/20 0.70
MEN1 O00255 1/20 0.70
ABL1 P00519 1/20 0.70
ALPL P05186 1/20 0.70
GAA P10253 1/20 0.70
KMT2A Q03164 1/20 0.70
RIN1 Q13671 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3554423 0.99 ADRB2 (0.85) ADRB2DRD2DRD4KDM1ATBXA2R
SCHEMBL3552585 0.99 ADRB2 (0.85) ADRB2DRD2DRD4KDM1ATBXA2R
SCHEMBL13344579 0.99 ADRB2 (0.85) ADRB2DRD2DRD4KDM1ATBXA2R
Hydrochloric Acid SCHEMBL3544374 0.97 ADRB2 (0.82) ADRB2DRD2DRD4KDM1ATBXA2R
SCHEMBL9592271 0.91 ADRB2 (1.00) ADRB2DRD2DRD4KDM1ATBXA2R
(+)-Higenamine SCHEMBL5898932 0.87 DRD2 (0.97) ADRB2DRD2DRD4KDM1ATBXA2R
(-)-Higenamine SCHEMBL5898916 0.87 DRD2 (0.97) ADRB2DRD2DRD4KDM1ATBXA2R
Bromide SCHEMBL5097119 0.85 ADRB2 (0.75) ADRB2DRD2DRD4KDM1ATBXA2R
Higenamine SCHEMBL636788 0.85 DRD2 (1.00) ADRB2DRD2DRD4KDM1ATBXA2R
(+)-Higenamine SCHEMBL5898913 0.85 DRD2 (1.00) ADRB2DRD2DRD4KDM1ATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718672-B2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-05-18 US disclosed
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy MILLER DUANE D 2008-02-07 US disclosed
US-20070270460-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE MILLER DUANE D 2007-11-22 US disclosed
US-7241774-B2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-07-10 US disclosed
US-20040019078-A1 Substituted tetrahydroisoquinoline compounds, methods of making, and their use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION,THE 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy BAD, TP53, MCL1 ADRB2 4360/4885ADRB1 4249/4885ADRB3 4250/4885
US-20070270460-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE BAX, CASP3, BAD ADRB2 2868/4885ADRB1 2820/4885ADRB3 2244/4885
US-20040019078-A1 Substituted tetrahydroisoquinoline compounds, methods of making, and their use BAD, BAX, CASP3 ADRB2 2857/4885ADRB1 2762/4885ADRB3 2227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.